Skip to Content

Answers (1)

Official Answer by 30 Nov 2016

Sandoz's Erelzi (etanercept-szzs) is a biosimilar for the reference product Enbrel (etanercept) approved in August 2016. Erelzi is the first approved biosimilar for etanercept, and the third biosimilar available on the US market.

A biosimilar is a biological product that is “highly similar” to a U.S.-licensed reference biological (in this case Enbrel). The FDA has determined there are no clinically meaningful differences between the biological product Erelzi and the original reference product Enbrel in terms of safety, purity, and potency. However, a biosimilar is not considered a “generic” in the same way that a traditional drug is determined to be a generic.

Erelzi is used for the same five indications found on Enbrel product labeling:
- rheumatoid arthritis,
- polyarticular juvenile idiopathic arthritis,
- psoriatic arthritis,
- ankylosing spondylitis, and
- plaque psoriasis.

It’s important to note that Erelzi is not an interchangeable product with Enbrel at the pharmacy level. Physicians must write the prescription specifically for Erelzi, as pharmacists cannot automatically substitute Erelzi for Enbrel.

Votes: +0 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What are the active ingredients in Qtern?

Posted 5 Jul 2017 1 answerFAQ by

What is the Siliq REMS Program?

Posted 5 Jul 2017 1 answerFAQ by

What type of drug is Emflaza?

Posted 5 Jul 2017 1 answerFAQ by

What is Parsabiv used to treat?

Posted 5 Jul 2017 1 answerFAQ by

Is Xyzal available over-the-counter?

Posted 5 Jul 2017 1 answerFAQ by